Lumoxiti Alternatives Compared
| Lumoxiti (moxetumomab pasudotox) | Cladribine | Intron A (interferon alfa-2b) |
|
|---|
| Lumoxiti (moxetumomab pasudotox) | Cladribine | Intron A (interferon alfa-2b) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hairy Cell Leukemia. Lumoxiti may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Sclerosis, Hairy Cell Leukemia. Cladribine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, Angioblastoma, Condylomata Acuminata, Hairy Cell Leukemia, Hepatitis B, Hepatitis C, Immune... View more |
Related suggestions Hairy Cell Leukemia
|
|||||||
| More about Lumoxiti (moxetumomab pasudotox) | More about Cladribine | More about Intron A (interferon alfa-2b) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Cladribine has an average rating of 8.6 out of 10 from a total of 9 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 11% reported a negative effect. |
Intron A has an average rating of 3.3 out of 10 from a total of 4 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 75% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Lumoxiti side effects |
View all Cladribine side effects |
View all Intron A side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
Lower cost generic |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Cladribine prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
|
|
||||||||
| Brand Names | ||||||||||
|
N/A |
Cladribine Novaplus, Mavenclad |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
1.4 hours |
6.7 hours |
3 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 72 drugs are known to interact with Lumoxiti:
|
A total of 500 drugs are known to interact with Cladribine:
|
A total of 260 drugs are known to interact with Intron A:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
September 13, 2018 |
March 29, 2019 |
N/A |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.